Trial Profile

A phase II trial of BGC-515 in solid tumours

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BGC 515 (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors BridGene Biosciences

Most Recent Events

28 Jan 2026 According to BridGene Biosciences media release, Proceeds from the financing will be used to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2.
18 Nov 2025 New trial record
16 Oct 2025 According to BridGene Biosciences media release, the company plans to initiate the trial in 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com